Phase I Protocol to Assess Safety of Biomarker-Driven Therapy Using Selective Immune Activators in Combination With Anti-PD-1 (Nivolumab) in Patients With First Recurrence of Glioblastoma
Phase of Trial: Phase I
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Epacadostat (Primary) ; Ipilimumab (Primary) ; MK 4166 (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 29 Mar 2019 Status changed from not yet recruiting to recruiting.
- 11 Mar 2019 Planned initiation date changed from 1 Feb 2019 to 1 Apr 2019.
- 18 Feb 2019 Planned End Date changed from 1 Jan 2024 to 1 Feb 2024.